Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.061
Neutral
RSI(14)
48.258
Neutral
STOCH(KDJ)(9,3,3)
20.012
Sell
ATR(14)
0.368
High Vlolatility
CCI(14)
-96.630
Neutral
Williams %R
76.190
Sell
TRIX(12,20)
0.280
Sell
StochRSI(14)
34.215
Buy
BioCryst Pharmaceuticals Inc
BCRX7.290USD
+0.160+2.24%
Close 12/18, 16:00（ET）Quotes delayed by 15 min
1.53BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of BioCryst Pharmaceuticals Inc
Currency: USD Updated: 2025-12-17Key Insights
BioCryst Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 11/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.64.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioCryst Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Buy
Current Rating
20.636
Target Price
+168.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
BioCryst Pharmaceuticals Inc Highlights
StrengthsRisks
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 66.42% year-on-year.
Undervalued
The company’s latest PE is -164.63, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 213.88M shares, increasing 6.83% quarter-over-quarter.
Held by Joel Greenblatt
Star Investor Joel Greenblatt holds 343.77K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-17The current financial score of BioCryst Pharmaceuticals Inc is 8.77, ranking 35/404 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 159.40M, representing a year-over-year increase of 36.14%, while its net profit experienced a year-over-year increase of 191.92%.
Score
Financials
6.09
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.77
BioCryst Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2025-12-17The current valuation score of BioCryst Pharmaceuticals Inc is 8.35, ranking 50/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -164.63, which is -97.65% below the recent high of -3.87 and -10.85% above the recent low of -182.49.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 11/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-17The current earnings forecast score of BioCryst Pharmaceuticals Inc is 8.40, ranking 129/404 in the Biotechnology & Medical Research industry. The average price target for BioCryst Pharmaceuticals Inc is 21.00, with a high of 30.00 and a low of 9.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
20.636
Target Price
+168.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
BioCryst Pharmaceuticals Inc
BCRX
10
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-17The current price momentum score of BioCryst Pharmaceuticals Inc is 6.99, ranking 153/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.96 and the support level at 6.50, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
7.410
Sell
MA10
7.522
Sell
MA20
7.358
Sell
MA50
7.170
Buy
MA100
7.605
Sell
MA200
8.256
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-17The current institutional shareholding score of BioCryst Pharmaceuticals Inc is 10.00, ranking 1/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 103.62%, representing a quarter-over-quarter decrease of 2.11%. The largest institutional shareholder is The Vanguard, holding a total of 21.75M shares, representing 10.33% of shares outstanding, with 0.01% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Deerfield Management Company, L.P.
State Street Investment Management (US)
Kynam Capital Management LP
Two Sigma Investments, LP
UBS Financial Services, Inc.
Arrowstreet Capital, Limited Partnership
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-17The current risk assessment score of BioCryst Pharmaceuticals Inc is 6.45, ranking 29/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.80. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.81
VaR
+5.46%
240-Day Maximum Drawdown
+42.63%
240-Day Volatility
+52.46%
Return
Best Daily Return
60 days
+9.64%
120 days
+9.81%
5 years
+27.85%
Worst Daily Return
60 days
-8.81%
120 days
-8.81%
5 years
-37.81%
Sharpe Ratio
60 days
-0.76
120 days
-1.38
5 years
+0.15
Risk Assessment
Maximum Drawdown
240 days
+42.63%
3 years
+61.33%
5 years
+79.10%
Return-to-Drawdown Ratio
240 days
-0.21
3 years
-0.18
5 years
-0.12
Skewness
240 days
+1.72
3 years
+1.23
5 years
+0.35
Volatility
Realised Volatility
240 days
+52.46%
5 years
+61.41%
Standardised True Range
240 days
+4.92%
5 years
+7.21%
Downside Risk-Adjusted Return
120 days
-237.57%
240 days
-237.57%
Maximum Daily Upside Volatility
60 days
+32.09%
Maximum Daily Downside Volatility
60 days
+37.09%
Liquidity
Average Turnover Rate
60 days
+1.55%
120 days
+1.86%
5 years
--
Turnover Deviation
20 days
-12.03%
60 days
-3.08%
120 days
+16.47%
Peer Comparison
Biotechnology & Medical Research
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.73 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.32 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Viridian Therapeutics Inc
VRDN
8.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of BioCryst Pharmaceuticals Inc?
The TradingKey Stock Score provides a comprehensive assessment of BioCryst Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of BioCryst Pharmaceuticals Inc’s performance and outlook.
How do we generate the financial health score of BioCryst Pharmaceuticals Inc?
To generate the financial health score of BioCryst Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects BioCryst Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of BioCryst Pharmaceuticals Inc.
How do we generate the company valuation score of BioCryst Pharmaceuticals Inc?
To generate the company valuation score of BioCryst Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare BioCryst Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of BioCryst Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of BioCryst Pharmaceuticals Inc.
How do we generate the earnings forecast score of BioCryst Pharmaceuticals Inc?
To calculate the earnings forecast score of BioCryst Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on BioCryst Pharmaceuticals Inc’s future.
How do we generate the price momentum score of BioCryst Pharmaceuticals Inc?
When generating the price momentum score for BioCryst Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of BioCryst Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for BioCryst Pharmaceuticals Inc.
How do we generate the institutional confidence score of BioCryst Pharmaceuticals Inc?
To generate the institutional confidence score of BioCryst Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about BioCryst Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of BioCryst Pharmaceuticals Inc.
How do we generate the risk management score of BioCryst Pharmaceuticals Inc?
To assess the risk management score of BioCryst Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of BioCryst Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of BioCryst Pharmaceuticals Inc.
